A revised version of the EUCAST guidance document on “When there are no breakpoints” has been published. The latest reformatted version contains further advice to help laboratories interpret…
The EUCAST responses to comments received on the public consultation for proposed breakpoints for new anaerobic bacterial species are published. Many useful comments were received which have…
An updated version (16.1) of the clinical breakpoint tables has been published, including breakpoints for additional anaerobic bacterial species. New breakpoints are now available for Fusobacterium…
Review of breakpoints for ertapenem, imipenem, imipenem-relebactam, meropenem, meropenem-vaborbactam and ceftazidime-avibactam are ongoing. Following the second of two consultations, EUCAST will…
The EUCAST subcommittee on the role of whole genome sequencing (WGS) in antimicrobial susceptibility testing (AST) has published its second review: The role of whole genome sequencing in antimicrobial…
The rationale document for gepotidacin has been published. This follows the recent publication of gepotidacin breakpoints in version 16.0 of the breakpoint tables for Escherichia coli, Staphylococcus…
Breakpoints for antimicrobial agents against the following species are proposed: Clostridium innocuum, Clostridium ramosum, Clostridium septicum, Clostridium tertium, Cutibacterium avidum, Finegoldia…
Following a review of the comments submitted to the recent consultation on carbapenem breakpoints for Gram-negative bacteria, a further proposal on meropenem breakpoints on Pseudomonas and …
Updated versions of MIC:ZD correlations have been published for relevant bacterial species. These correlations form the basis of validation of zone diameter criteria for disk diffusion methodology.
A public consultation on revised carbapenem (with and without inhibitors) and ceftazidime-avibactam breakpoints against Gram-negative bacteria has been published. The revised breakpoints are presented…
